<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00912392</url>
  </required_header>
  <id_info>
    <org_study_id>SIM-69</org_study_id>
    <nct_id>NCT00912392</nct_id>
  </id_info>
  <brief_title>Etoposide-Carboplatin Alone or With Endostar for Extensive Disease Small Cell Lung Cancer (ED-SCLC)</brief_title>
  <official_title>Etoposide-Carboplatin (EC) Versus EC Plus Endostar in Patients With Extensive Disease Small Cell Lung Cancer (ED-SCLC): Randomized, Open Label, Placebo-controlled, Multicentre Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:

      The effect of existing treatment modalities of extensive disease small-cell lung cancer
      (ED-SCLC) is unsatisfactory. Progress of new strategies including more efficient therapy is
      wanted. Endostar® (Rh-endostatin Injection) may have anti-tumor activity by against vascular
      endothelial growth factor for initial treatment. This study was designed to evaluate the
      safety and efficacy of Endostar® combined with etoposide-carboplatin (EC) chemotherapy in
      patients with ED-SCLC seeking for more effective treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methods:

      In this randomized, open label, placebo-controlled, multicentre trial, 120 patients are
      planned to be enrolled at random into 2 arms(1:1) from 10 centers between June 2009 and June
      2011. The leader units are Shanghai Chest Hospital Affiliated to Shanghai Jiao-Tong
      University. Main eligibility criteria are histological or cytological diagnosis of ED-SCLC,
      with an age of 18-75 years. All eligible patients receive etoposide-carboplatin (EC) alone or
      with endostar® for 4-6 cycles (21 days for 1 cycle). In arm1 patients receive endostar®
      7.5mg/m2 on day 1 to day 14, etoposide 60 mg/m2 on day 1 to day 5 and carboplatin AUC 5 on
      day 1. In arm2 patients receive etoposide 60 mg/m2 on day 1 to day 5 and carboplatin AUC 5 on
      day 1.

      Primary endpoint: progress free survival (PFS).

      Secondary endpoint: progress free survival at 6 months, overall survival (OS), objective
      response rate (ORR), clinical benefit rate (CBR), Response duration, time to progression(TTP)
      and quality of life (QOL).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>Oct-30-2012</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Oct-30-2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Oct-30-2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate (CBR)</measure>
    <time_frame>Oct-30-2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response duration</measure>
    <time_frame>Oct-30-2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression(TTP)</measure>
    <time_frame>Oct-30-2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QOL)</measure>
    <time_frame>Oct-30-2012</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">138</enrollment>
  <condition>Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Etoposide-Carboplatin with Endostar</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endostar® 7.5mg/m2 on day 1 to day 14, etoposide 60 mg/m2 on day 1 to day 5 and carboplatin AUC 5 on day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Etoposide-Carboplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Etoposide 60 mg/m2 on day 1 to day 5 and carboplatin AUC 5 on day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Endostar</intervention_name>
    <description>Endostar® 7.5mg/m2 on day 1 to day 14</description>
    <arm_group_label>Etoposide-Carboplatin with Endostar</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide-Carboplatin</intervention_name>
    <description>Etoposide 60 mg/m2 on day 1 to day 5 and carboplatin AUC 5 on day 1.</description>
    <arm_group_label>Etoposide-Carboplatin with Endostar</arm_group_label>
    <arm_group_label>Etoposide-Carboplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically diagnosed SCLC;

          -  Age of 18-75 years;

          -  Life expectancy ＞ 3 months;

          -  Adequate hematologic, renal, and hepatic function;

          -  ECOG PS 0-2;

        Exclusion Criteria:

          -  Brain metastases;

          -  Clinically significant cardiovascular disease;

          -  Presence of hepatic and renal dysfunction;

          -  Evidence of bleeding diathesis or coagulopathy

          -  Pregnant or lactating woman;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shun Lu, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Chest Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shanghai Chest Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200039</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2009</study_first_submitted>
  <study_first_submitted_qc>June 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2009</study_first_posted>
  <last_update_submitted>August 31, 2014</last_update_submitted>
  <last_update_submitted_qc>August 31, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

